# A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

> **NCT04655807** · PHASE2 · WITHDRAWN · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** JNJ-64304500
- **DRUG:** Placebo
- **DRUG:** Adalimumab
- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT04655807
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-03-03
- **Primary completion:** 2023-05-24
- **Final completion:** 2023-09-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Decision.
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04655807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04655807, "A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04655807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*